Abstract
BACKGROUND--The equivalence of generic beclomethasone dipropionate (BDP) formulations with their innovator counterpart must be demonstrated if generic formulations are to be used. This study has examined the aerodynamic particle size distributions of both innovator and generic formulations of BDP and the effect of a large volume spacer (Volumatic) on these distributions. METHODS--Aerosol clouds of three formulations of BDP delivering 250 micrograms per metered dose were characterised using a high precision multistage liquid impinger, and the amount of drug in different particle size bands was determined by spectrophotometric assay. RESULTS--The mean (SD) respirable fractions of Becloforte, Beclazone, and Filair without the spacer (n = 10) were 24.1 (2.1)%, 23.1 (2.7)%, and 23.0 (2.1)% respectively; however, the ratio of deposition on stage 4 of the impinger to that on stage 3 was lower for Beclazone and for Filair than for Becloforte, implying a smaller proportion of fine particles for the generic products. When the three products delivered via the Volumatic spacer device were compared, the respirable fraction for Becloforte (n = 10) was 25.0 (4.0)%, but those of Beclazone (n = 10) and Filair (n = 11) were 16.0 (1.9)% and 14.6 (3.4)%. Repeat testing (n = 5) at a later date showed higher mean respirable fractions for all three products, but a trend towards the highest respirable fraction for Becloforte, and the same rank order for the other two products. CONCLUSIONS--These in vitro findings suggest that the particle size distributions of the two generic formulations of BDP are not equivalent to that of the innovator product. Some differences in particle size distributions might not have been detected by a twin impinger. Clinical testing would be required to assess the therapeutic equivalence of innovator and generic corticosteroid products used with or without spacer devices.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brown P. H., Blundell G., Greening A. P., Crompton G. K. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax. 1990 Oct;45(10):736–739. doi: 10.1136/thx.45.10.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cyr T. D., Graham S. J., Li K. Y., Lovering E. G. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res. 1991 May;8(5):658–660. doi: 10.1023/a:1015825311750. [DOI] [PubMed] [Google Scholar]
- Hallworth G. W., Westmoreland D. G. The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers. J Pharm Pharmacol. 1987 Dec;39(12):966–972. doi: 10.1111/j.2042-7158.1987.tb03142.x. [DOI] [PubMed] [Google Scholar]
- Newman S. P. Aerosol generators and delivery systems. Respir Care. 1991 Sep;36(9):939–951. [PubMed] [Google Scholar]
- O'Callaghan C., Lynch J., Cant M., Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax. 1993 Jun;48(6):603–606. doi: 10.1136/thx.48.6.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Toogood J. H., Baskerville J., Jennings B., Lefcoe N. M., Johansson S. A. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis. 1984 May;129(5):723–729. doi: 10.1164/arrd.1984.129.5.723. [DOI] [PubMed] [Google Scholar]